Robert W. Baird Cuts Cellectis (NASDAQ:CLLS) Price Target to $8.00

by · The Cerbat Gem

Cellectis (NASDAQ:CLLS – Free Report) had its price target lowered by Robert W. Baird from $10.00 to $8.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Several other research analysts have also weighed in on the company. Wells Fargo & Company dropped their target price on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Barclays assumed coverage on Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Finally, Citizens Jmp reiterated a “market perform” rating on shares of Cellectis in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $5.46.

Read Our Latest Analysis on CLLS

Cellectis Trading Up 6.2%

Shares of NASDAQ:CLLS opened at $1.46 on Tuesday. The firm has a fifty day moving average of $2.90 and a two-hundred day moving average of $3.28. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. Cellectis has a 12-month low of $1.25 and a 12-month high of $5.48. The firm has a market capitalization of $146.50 million, a P/E ratio of -2.25 and a beta of 2.92.

Cellectis (NASDAQ:CLLS – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The business had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cellectis stock. Lido Advisors LLC acquired a new stake in Cellectis S.A. (NASDAQ:CLLS – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is currently owned by institutional investors.

Key Stories Impacting Cellectis

Here are the key news stories impacting Cellectis this week:

  • Positive Sentiment: Cellectis plans to prioritize two preclinical in vivo gene-editing programs, a strategy that could provide a more focused path toward genetic medicines and potentially reduce internal development costs. The company is also seeking partners to continue development of the discontinued CAR-T programs. Cellectis Exits Two CAR-T Programs
  • Neutral Sentiment: An analysis characterized the pivot as an “all or nothing” transition that warrants monitoring. The opportunity depends on whether Cellectis can demonstrate meaningful progress with its early-stage in vivo gene-editing platform. Cellectis In Vivo Gene-Editing Analysis
  • Neutral Sentiment: Citizens JMP reiterated a Market Perform rating, indicating limited conviction that the strategic transformation will drive near-term outperformance. Citizens JMP Market Perform Rating
  • Negative Sentiment: Analysts lowered their expectations for Cellectis. Wells Fargo reduced its price target to $3.00, while Robert W. Baird also lowered its expectations following the pipeline pivot. These actions reflect weaker near-term visibility after the company abandoned internal development of two CAR-T candidates. Wells Fargo Lowers Cellectis Price Target Baird Lowers Cellectis Expectations
  • Negative Sentiment: Several law firms announced investigations into whether Cellectis complied with federal securities laws in connection with disclosures surrounding the strategic transformation. These announcements add potential legal and reputational overhang, although they do not establish wrongdoing. Holzer and Holzer Cellectis Investigation Frank R. Cruz Cellectis Investigation

Cellectis Company Profile

(Get Free Report)

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.

Featured Stories